Cargando...
Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia
Approved therapies that target the B-cell receptor (BCR) signaling pathway, such as ibrutinib and idelalisib, are known to show activity in chronic lymphocytic leukemia (CLL) via their direct effects on crucial survival pathways in malignant B cells. However, these therapies also have effects on T c...
Guardado en:
| Publicado en: | Blood Adv |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society of Hematology
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728096/ https://ncbi.nlm.nih.gov/pubmed/29296833 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017006809 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|